Trade Risk Screening

Pharmaceutical trade compliance,
without manual supplier risk chaos.

Screen suppliers, manufacturers, exporters, logistics providers, directors, and beneficial owners against sanctions, PEP, watchlist, debarment, jurisdiction, and ownership-risk signals — then package the review into a reviewable case.

Live today: core Verifex screening for sanctions, PEP, watchlist, debarment, and entity risk. Planned: pharma trade-case workflow, document checklist automation, and pharma-specific case reports.

The operational problem

Manual supplier review creates inconsistent decisions and weak audit trails.

Pharmaceutical importers often collect supplier documents manually, check manufacturer names across different sources, review ownership risk separately, and store evidence in spreadsheets or email threads. This creates inconsistent decisions, weak audit trails, and slow supplier onboarding.

Fragmented document collection

Required import documents arrive from different parties at different times. There is no single place to track completeness or attach them to a screening case.

Inconsistent entity checks

Supplier names, manufacturer identities, and beneficial owners are checked inconsistently — or not at all — because the process is manual and there is no structured workflow.

No reviewable output

When regulators or internal auditors ask what was checked, when, and by whom, the answer is usually buried in email threads and spreadsheet notes.

Screening coverage

What Verifex checks in a pharmaceutical trade case

Every party in the supply chain is a potential risk surface. The live Verifex API screens people and organizations through configured sanctions, PEP, watchlist, debarment, and entity-risk sources. Pharma-specific trade case packaging is planned.

Supplier and manufacturer names

Screen every counterparty name against sanctions, PEP, watchlist, and debarment sources before contracts or purchase orders are approved.

Exporters, distributors, and logistics providers

Identify all parties in the shipment chain and run each one through the same screening workflow.

Directors and beneficial owners

Trace corporate ownership to identify directors and UBOs, then screen them against PEP and watchlist signals.

Sanctions, PEP, and watchlist exposure

Check every screened party against OFAC, EU, UN, UK, and other configured sanctions and PEP sources.

Debarment and high-risk jurisdiction signals

Flag parties appearing on public debarment lists such as World Bank Debarred and identify high-risk origin or destination jurisdictions.

Uploaded document completeness and evidence trail

Track which required import documents have been uploaded, which are missing, and attach them to the audit case.

Data model

Screening data the workflow can connect

The trade case workflow is designed to support multiple evidence layers. Available sources are active today. Planned sources are on the integration roadmap pending customer validation.

Core screening

Available

Verifex sanctions, watchlist, and PEP screening against configured sources including OFAC, EU, UN, UK, and other enabled feeds.

Customer-uploaded documents

Planned

Invoices, contracts, certificates, import permits, and other trade documents uploaded and attached to a pharma trade case.

Public debarment sources

Available

World Bank Debarred and other public debarment registries as configured sources.

Manual evidence links

Planned

Reviewers can attach URLs to public registries, regulatory databases, or other external evidence sources.

Public regulatory evidence

Planned

Public registry and regulatory evidence sources where legally and technically appropriate. Can be attached as manual evidence or configured source.

Licensed PEP, adverse media, and ownership data

Planned

Licensed third-party providers for enhanced PEP coverage, adverse media, and corporate registry data. Available as configured source after customer validation.

Import document checklist

Planned document workflow: customer-uploaded documents, tracked in the case.

Verifex does not determine whether a pharmaceutical product is legally approved for import. It helps teams organize documents, extract entities, screen counterparties, and preserve evidence for internal compliance review.

The document checklist workflow is planned. The current live product supports core screening API keys and screening results; pharma-specific document upload, checklist automation, and case reports are roadmap items.

Important limitation

Verifex does not approve, register, certify, test, inspect, or authorize pharmaceutical products. Final regulatory, legal, import, medical, and commercial decisions remain with the responsible company, regulator, customs authority, qualified professional, or legal advisor.

Document checklist

trade case
  • Sales contract
  • Commercial invoice
  • Certificate of origin
  • Certificate of analysis
  • GMP certificate
  • Product registration proof
  • Import permit
  • Packing list
  • Bill of lading or airway bill
  • Cold-chain / temperature records (where required)
  • Special permits for controlled, potent, toxic, or restricted substances (where applicable)

Workflow

Five steps from supplier contact to reviewable report.

The workflow below describes the planned pharma trade-case product. The live capability today is the standard Verifex screening API for people, companies, suppliers, directors, and beneficial owners.

01

Create a trade case

Start with the importer, supplier, manufacturer, product name, country of origin, and available documents.

02

Extract entities from documents

Capture company names, directors, owners, manufacturers, shipment parties, invoice numbers, batch numbers, and dates.

03

Screen every party

Run suppliers, manufacturers, distributors, logistics providers, directors, and beneficial owners through Verifex screening.

04

Attach public or licensed evidence

Link registry records, debarment data, GMP/GDP evidence, adverse media, or corporate ownership data where available.

05

Generate audit report

Export a structured JSON report with source links, timestamps, risk results, reviewer notes, and final internal decision.

Risk output

Structured results, not a black-box score.

Each trade case produces a structured risk output showing what was checked, what was found, what is missing, and what requires internal manual review. The final decision always remains with the responsible compliance team.

The example below is illustrative. It shows a realistic output structure — not a guarantee of any specific result.

Example risk output

Illustrative only — not a guarantee of result

risk: medium
SupplierNo sanctions match
ManufacturerRegistry evidence — manual review required
Beneficial ownerPEP possible match — manual review required
Certificate of analysisUploaded
GMP certificateMissing

Internal manual review required. Final decision with responsible compliance team.

API reference

Planned trade case API endpoints

The current product supports core screening through the standard Verifex API. The pharma trade case workflow below is a planned API surface and should be treated as roadmap documentation until these endpoints are released.

Endpoints

POST
Planned API

/v1/trade/pharma/cases

Planned: create a new trade case

POST
Planned API

/v1/trade/pharma/cases/:id/entities

Planned: add screened entities to a case

POST
Planned API

/v1/trade/pharma/cases/:id/documents

Planned: upload or attach a document

POST
Planned API

/v1/trade/pharma/cases/:id/screen

Planned: run screening on all case entities

GET
Planned API

/v1/trade/pharma/cases/:id

Planned: retrieve case details and status

GET
Planned API

/v1/trade/pharma/cases/:id/report

Planned: export structured audit report

request.json
{
  "importer": {
    "name": "ABC Pharma MMC",
    "country": "AZ"
  },
  "supplier": {
    "name": "Example Medical Trading GmbH",
    "country": "DE"
  },
  "manufacturer": {
    "name": "Example Laboratories GmbH",
    "country": "DE"
  },
  "product": {
    "name": "Example Medicine 500mg",
    "activeIngredient": "Example Ingredient",
    "dosageForm": "tablet",
    "batchNumber": "B-2026-041"
  },
  "documents": [
    "commercial_invoice",
    "certificate_of_origin",
    "certificate_of_analysis",
    "gmp_certificate"
  ]
}
response.json
{
  "caseId": "pharma_case_01J...",
  "status": "manual_review_required",
  "riskLevel": "medium",
  "screening": {
    "supplier": {
      "sanctions": "clear",
      "pep": "clear",
      "watchlist": "clear"
    },
    "manufacturer": {
      "sanctions": "clear",
      "registryEvidence": "needs_manual_review"
    },
    "beneficialOwners": [
      {
        "name": "Example Owner",
        "pep": "possible_match",
        "decision": "manual_review_required"
      }
    ]
  },
  "documents": {
    "commercial_invoice": "uploaded",
    "certificate_of_origin": "uploaded",
    "certificate_of_analysis": "uploaded",
    "gmp_certificate": "missing"
  },
  "audit": {
    "reportAvailable": true,
    "evidenceLogEntries": 8
  }
}

Compliance disclaimer

Verifex does not approve, register, certify, test, inspect, or authorize pharmaceutical products. Verifex is a data and technology layer that helps compliance teams screen counterparties, ownership structures, risk signals, and supporting documents. Final regulatory, legal, import, medical, and commercial decisions remain with the responsible company, regulator, customs authority, qualified professional, or legal advisor.

Get started

Bring supplier risk, documents, and audit evidence into one workflow.

Start with the live core screening API today. Pharma trade-case endpoints, document workflow, and pharma-specific case reports are planned.

Verifex provides risk screening and evidence support. Screening results are not legal advice, regulatory approval, or a substitute for qualified compliance review. Verifex does not approve, register, certify, test, inspect, or authorize pharmaceutical products.

Existing Verifex API keys work for current core screening. Trade case endpoints are planned.